作者
Jorne Lionel Biccler, Ingrid Glimelius, Sandra Eloranta, Knut B Smeland, Peter de Nully Brown, Lasse Hjort Jakobsen, Henrik Frederiksen, Mats Jerkeman, Alexander Fosså, Therese ML Andersson, Harald Holte, Martin Bøgsted, Tarec Christoffer El-Galaly, Karin E Smedby
发表日期
2019/3/20
期刊
Journal of Clinical Oncology
卷号
37
期号
9
页码范围
703-713
出版商
American Society of Clinical Oncology
简介
PURPOSE
Estimates of short- and long-term survival for young patients with classic Hodgkin lymphoma (cHL) are of considerable interest. We investigated cHL prognosis in the era of contemporary treatment at different milestones during the follow-up.
PATIENTS AND METHODS
On the basis of a Nordic cohort of 2,582 patients diagnosed at ages 18 to 49 years between 2000 and 2013, 5-year relapse risks and 5-year restricted losses in expectation of lifetime were estimated for all patients and for patients who achieved event-free survival (EFS) for 12 (EFS12), 24 (EFS24), 36 (EFS36) or 60 (EFS60) months. The median follow-up time was 9 years (range, 2.9 to 16.8 years).
RESULTS
The 5-year overall survival was 95% (95% CI, 94% to 96%). The 5-year risk of relapse was 13.4% (95% CI, 12.1% to 14.8%) overall but decreased to 4.2% (95% CI, 3.8% to 4.6%) given that patients reached EFS24. Relapse risk for …
学术搜索中的文章
JL Biccler, I Glimelius, S Eloranta, KB Smeland… - Journal of Clinical Oncology, 2019